TABLE 2

Evaluation of rs2040410 and rs7454108 in subjects participating in the British Diabetic Association, Denmark, Human Biological Data Interchange, Poland, and U.K. T1DGC cohorts and in subjects in the DAISY population analyzed by restriction digest and Taqman

DR3/4-DQ8Not DR3/4-DQ8
n1,1913,828
T1DGC subjects
    rs2040410 A/G and rs7454108 C/T1,121 (94.1)12 (0.3)
    rs2040410 A/A and rs7454108 C/T52 (4.4)1 (0.03)
    rs2040410 G/G and rs7454108 C/T7 (0.6)1,384 (36.2)
    rs2040410 A/G and rs7454108 C/C or T/T9 (0.8)1,086 (28.4)
    rs2040410 A/A or G/G and rs7454108 C/C or T/T2 (0.2)1,345 (35.1)
DAISY subjects
    rs2040410 A/G and rs7454108 C/T69 (100)0 (0)
    rs2040410 A/A and rs7454108 C/T0 (0)0 (0)
    rs2040410 G/G and rs7454108 C/T0 (0)27 (36.5)
    rs2040410 A/G and rs7454108 C/C or T/T0 (0)16 (21.6)
    rs2040410 A/A or G/G and rs7454108 C/C or T/T0 (0)31 (41.9)
  • Data are n (%) unless otherwise indicated.